FDA Review Status for Pediatric Multiple Vitamins Injection by Apotex
The FDA has received an application (ANDA210671) from Apotex for a pediatric multiple vitamins injection.
Published: July 28, 2026
Updated: July 28, 2026
Author: Humanexa Intelligence
Therapeutic area: Nutritional Support / Injectable Vitamins
Asset: Apotex
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Apotex
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's review of Apotex's pediatric multiple vitamins injection is significant as it may alter the competitive landscape in the nutritional support market. Companies should prepare to adapt their strategies based on the outcome of this application and potential market entry by Apotex.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's decision timeline and any subsequent market entry by Apotex.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.